Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission
JAMA Internal Medicine · 01.07.2026 · 186 (7) · 898
DOI: 10.1001/jamainternmed.2026.0980 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.07.2026. Verfasst von Jennifer Leon und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Notre Dame, Notre Dame, Indiana. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cohort study evaluates all products targeted by the Federal Trade Commission from 2023 to 2025 and analyzes how delistings have impacted periods of patent protection.
Autor:innen und Institutionen
- University of Notre Dame, Notre Dame, Indiana.
- Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- University of Alabama School of Law, Tuscaloosa.
- Harvard Medical School, Boston, Massachusetts.
- Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology, and Allergy, Department of Medicine, University of California, Los Angeles.
Zitieren
APA
Leon, J., Tu, S. S., Kesselheim, A. S., & Feldman, W. B. (2026). Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission. JAMA Internal Medicine, 186(7), 898. https://doi.org/10.1001/jamainternmed.2026.0980
Vancouver
Leon J, Tu SS, Kesselheim AS, Feldman WB. Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission. JAMA Internal Medicine. 2026;186(7):898. doi:10.1001/jamainternmed.2026.0980
BibTeX
@article{Leon2026,
author = {Leon, Jennifer and Tu, S Sean and Kesselheim, Aaron S and Feldman, William B},
title = {Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission},
journal = {JAMA Internal Medicine},
year = {2026},
volume = {186},
number = {7},
pages = {898},
doi = {10.1001/jamainternmed.2026.0980}
}
EUVIMED